TriangleONT01 + Gem/Nab-Paclitaxel (NCT06904378)
ONT01 + Gem/Nab-Paclitaxel trial for Metastatic Pancreatic Ductal Adenocarcinoma (Second Line) (NCT06904378). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic pancreatic cancer, as a second line treatment.
The idea: ONT01 is a drug that activates CD11b, a protein on immune cells. The researchers think this can reprogram the area around the tumor to overcome resistance to immunotherapy. It is given with standard gemcitabine and nab paclitaxel chemotherapy.
The study looks at dose and safety, to prepare for future studies adding PD-1 immunotherapy.
This phase 1 and 2 study plans 61 patients. At Washington University School of Medicine in St. Louis, Patrick Grierson leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.